Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY20 results · Jul–Sep 2019
Lincoln Pharmaceuticals reported revenue from operations of ₹110.60 crore (up 12.9% from Q2 FY19) and net profit of ₹17.99 crore (up 24.9% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a standalone basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 110.60 | 97.95 | +12.9% | 94.59 | +16.9% |
| Other income | 2.88 | 4.39 | −34.6% | 1.58 | +82.1% |
| Total income | 113.47 | 102.34 | +10.9% | 96.17 | +18.0% |
| Profit before tax | 23.62 | 17.96 | +31.5% | 17.00 | +38.9% |
| Net profit for the period | 17.99 | 14.41 | +24.9% | 12.16 | +47.9% |
| EPS, basic (₹) | 8.99 | 7.20 | +24.9% | 6.08 | +47.9% |
| Net margin (%) | 16.3 | 14.7 | 12.9 |
Standalone
- Filed with BSE
- 19 Nov 2019, 15:14 IST
- Board meeting
- 14 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE